FDA has cleared Viridian Therapeutics’ thyroid eye disease (TED) therapy Lumvoa (veligrotug-vvze), giving the company an entry point to a market long dominated by Amgen’s Tepezza (teprotumumab-trbw). The approval covers both chronic and active phases of TED, positioning Lumvoa as a competitive alternative for patients who previously had limited options. Viridian’s clearance also comes with label positioning intended to differentiate its dosing and administration profile versus Tepezza, according to coverage of the FDA action. The additional approved therapy is likely to intensify payer and treatment-decision dynamics in TED as Amgen faces a direct commercially viable competitor. The Reuters-style implication for the industry is straightforward: a second IGF-1R-targeted treatment in TED can reshape sequencing and contracting, while also raising the bar for real-world outcomes and tolerability as both drugs move through their respective lifecycle phases.